The US MEF2C Foundation has released updated figures from its patient registry, marking a significant milestone in the global effort to understand and treat MEF2C Haploinsufficiency Syndrome (MCHS).
The Numbers
The registry now stands at:
- 170 patients registered (up from previous counts)
- 168 consented to participate
- 150 lab reports approved
- 100 medical histories completed
- 122 with surveys
- 40 blood samples received
This represents a growing, curated body of longitudinal data that is becoming the backbone of clinical trial preparation.
Why the Registry Matters
Clinical trials for rare diseases don't start with the drug, they start with the data. Regulatory bodies need a baseline understanding of the disease before they'll approve a study to treat it. They need to know:
- How does the disease progress over time?
- What is the natural history of MHS at different ages?
- What are the baseline biomarkers we need to track?
Every patient registered in the US MEF2C Foundation registry contributes to answering those questions. The 100 completed medical histories alone create a baseline map of the condition across the US population. The blood samples will allow for future biomarker studies as the therapeutic pipeline matures.
Supporting the Global Effort
While the US MEF2C Foundation focuses heavily on the American patient population, the data it collects feeds into the global consortium's broader timeline. The registry is a key piece of the regulatory puzzle, working in parallel with:
- The Natural History Study (funded by the MEF2C Foundation UK's Pathways to Hope campaign)
- The Boston Children's Hospital assessments (led by Dr. Wendy Chung)
- The Volare Study at Weill Cornell Medical Center
None of these efforts exist in a vacuum. The US registry numbers are part of the global picture, helping the consortium meet the "three-year to human trials" target.
The Impact
Reaching 170 patients is a tangible victory for a community that numbers fewer than 500 people worldwide. It shows that families are engaged, data is being collected, and the community is building the evidence base needed to move treatments from the lab to the clinic.
For families waiting for answers, these registry numbers are proof that the work is continuing, one patient record at a time.